NCT05698264View on ClinicalTrials.gov

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Non Small Cell Lung CancerEGFR Gene MutationImmune Checkpoint Inhibitor
Interventions
DEVICE

concomitant TTFields treatment device to standard of care EGFR positive NSCLC treatment

Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.

DEVICE

concomitant TTFields treatment device to standard of care anti PD-1 NSCLC treatment

Concomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.

Trial Locations (1)

Unknown

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Nir Peled

OTHER

NCT05698264 - A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC | Biotech Hunter | Biotech Hunter